Author: admin

“Gastroparesis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroparesis Market.

The Gastroparesis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastroparesis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastroparesis treatment therapies with a considerable amount of success over the years.

• Gastroparesis companies working in the treatment market are CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others, are developing therapies for the Gastroparesis treatment

• Emerging Gastroparesis therapies in the different phases of clinical trials are- CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others are expected to have a significant impact on the Gastroparesis market in the coming years.

• In September 2024, The US Food and Drug Administration (FDA) has rejected the new drug application (NDA) submitted by Vanda Pharmaceuticals for the use of tradipitant in treating gastroparesis symptoms.

Gastroparesis Overview

Gastroparesis is a condition that affects the stomach’s ability to empty its contents due to nerve damage caused by diabetes. The condition occurs when high blood sugar levels over time damage the vagus nerve, which controls the muscles of the stomach. This results in delayed gastric emptying, causing symptoms like nausea, vomiting, bloating, abdominal pain, and feeling full quickly after eating. It can lead to poor blood sugar control and malnutrition. Treatment focuses on managing blood sugar levels, dietary changes, and medications to improve stomach motility and relieve symptoms.

Get a Free Sample PDF Report to know more about Gastroparesis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastroparesis-pipeline-insight

Emerging Gastroparesis Drugs Under Different Phases of Clinical Development Include:

• CIN-102: CinDome Pharma, Inc.

• Metoclopramide Nasal Spray: Evoke Pharma

• Tradipitant: Vanda Pharmaceuticals

• IW-9179: Ironwood Pharmaceuticals

• TAK-954: Takeda

• NG101: Neurogastrx, Inc

• CNSA-001: PTC Therapeutics

• velusetrag: Theravance Biopharma

• GM-611: Chugai Pharma

• Camicinal: GlaxoSmithKline

• PCS12852: Processa Pharmaceuticals

Gastroparesis Route of Administration

Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Gastroparesis Molecule Type

Gastroparesis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Gastroparesis Pipeline Therapeutics Assessment

• Gastroparesis Assessment by Product Type

• Gastroparesis By Stage and Product Type

• Gastroparesis Assessment by Route of Administration

• Gastroparesis By Stage and Route of Administration

• Gastroparesis Assessment by Molecule Type

• Gastroparesis by Stage and Molecule Type

DelveInsight’s Gastroparesis Report covers around 11+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Gastroparesis product details are provided in the report. Download the Gastroparesis pipeline report to learn more about the emerging Gastroparesis therapies

Some of the key companies in the Gastroparesis Therapeutics Market include:

Key companies developing therapies for Gastroparesis are – Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical, Teva Pharmaceutical, and others.

Gastroparesis Pipeline Analysis:

The Gastroparesis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastroparesis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroparesis Treatment.

• Gastroparesis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroparesis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastroparesis drugs and therapies

Gastroparesis Pipeline Market Drivers

• Growing prevalence of diabetes, Unmet medical need, Advancements in drug development, Improved awareness and diagnosis, Regulatory support for innovation, are some of the important factors that are fueling the Gastroparesis Market.

Gastroparesis Pipeline Market Barriers

• However, Limited effective treatment options, Challenges in drug development, Adverse side effects, High treatment costs, Regulatory challenges, and other factors are creating obstacles in the Gastroparesis Market growth.

Scope of Gastroparesis Pipeline Drug Insight

• Coverage: Global

• Key Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others

• Key Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others

• Gastroparesis Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies

• Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers

Request for Sample PDF Report for Gastroparesis Pipeline Assessment and clinical trials

Table of Contents

1. Gastroparesis Report Introduction

2. Gastroparesis Executive Summary

3. Gastroparesis Overview

4. Gastroparesis- Analytical Perspective In-depth Commercial Assessment

5. Gastroparesis Pipeline Therapeutics

6. Gastroparesis Late Stage Products (Phase II/III)

7. Gastroparesis Mid Stage Products (Phase II)

8. Gastroparesis Early Stage Products (Phase I)

9. Gastroparesis Preclinical Stage Products

10. Gastroparesis Therapeutics Assessment

11. Gastroparesis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gastroparesis Key Companies

14. Gastroparesis Key Products

15. Gastroparesis Unmet Needs

16 . Gastroparesis Market Drivers and Barriers

17. Gastroparesis Future Perspectives and Conclusion

18. Gastroparesis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera

“Giant-Cell Arteritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Giant-Cell Arteritis Market.

The Giant-Cell Arteritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Giant-Cell Arteritis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Giant-Cell Arteritis treatment therapies with a considerable amount of success over the years.

• Giant-Cell Arteritis companies working in the treatment market are AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others, are developing therapies for the Giant-Cell Arteritis treatment

• Emerging Giant-Cell Arteritis therapies in the different phases of clinical trials are- Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others are expected to have a significant impact on the Giant-Cell Arteritis market in the coming years.

• In June 2024, Johnson & Johnson has decided to discontinue a mid-stage trial evaluating its monoclonal antibody Tremfya (guselkumab) for the treatment of giant cell arteritis after it failed to meet the primary endpoint. As per a clinical update on clinicaltrials.gov, the Phase II THEIA study did not achieve the primary goal—the percentage of participants attaining glucocorticoid (GC)-free remission. Specific details regarding the results were not provided. However, the company reported “insufficient efficacy findings,” which led to the decision to halt further support for the study, according to a J&J spokesperson’s email to BioSpace. The spokesperson also mentioned that no new safety issues were identified.

• In April 2024, AbbVie has announced favorable initial results from the first phase of the Phase III SELECT-GCA trial assessing upadacitinib (RINVOQ; 15mg, once daily) in combination with a tapered steroid regimen for adults diagnosed with giant cell arteritis (GCA).

Giant-Cell Arteritis Overview

Giant-Cell Arteritis (GCA), also known as temporal arteritis, is an inflammatory condition that affects the blood vessels, particularly the large and medium-sized arteries in the head, including the temporal arteries. It primarily affects older adults, typically over the age of 50. The inflammation can lead to symptoms such as severe headaches, scalp tenderness, vision problems, and jaw pain while chewing. If left untreated, GCA can lead to serious complications, including permanent vision loss. The condition is typically treated with corticosteroids to reduce inflammation and prevent complications.

Get a Free Sample PDF Report to know more about Giant-Cell Arteritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight

Emerging Giant-Cell Arteritis Drugs Under Different Phases of Clinical Development Include:

• Rinvoq(upadacitinib): AbbVie

• Cosentyx (secukinumab): Novartis

• KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals

• Tremfya(guselkumab): Johnson & Johnson/ MorphoSys AG

• Baricitinib: Eli Lilly and Company

• Tocilizumab + Glucocorticoids (GCs): Roche Pharma

• Secukinumab: Novartis

• Guselkumab: Janssen Research & Development

• Tocilizumab: Hoffmann-La Roche

• adalimumab: Abbott

• Upadacitinib: AbbVie

Giant-Cell Arteritis Route of Administration

Giant-Cell Arteritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Giant-Cell Arteritis Molecule Type

Giant-Cell Arteritis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Giant-Cell Arteritis Pipeline Therapeutics Assessment

• Giant-Cell Arteritis Assessment by Product Type

• Giant-Cell Arteritis By Stage and Product Type

• Giant-Cell Arteritis Assessment by Route of Administration

• Giant-Cell Arteritis By Stage and Route of Administration

• Giant-Cell Arteritis Assessment by Molecule Type

• Giant-Cell Arteritis by Stage and Molecule Type

DelveInsight’s Giant-Cell Arteritis Report covers around 6+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Giant-Cell Arteritis product details are provided in the report. Download the Giant-Cell Arteritis pipeline report to learn more about the emerging Giant-Cell Arteritis therapies

Some of the key companies in the Giant-Cell Arteritis Therapeutics Market include:

Key companies developing therapies for Giant-Cell Arteritis are – Novartis, CSL, Kiniksa Pharmaceuticals, AbbVie, Johnson & Johnson, MorphoSys AG, and others.

Giant-Cell Arteritis Pipeline Analysis:

The Giant-Cell Arteritis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Giant-Cell Arteritis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Giant-Cell Arteritis Treatment.

• Giant-Cell Arteritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Giant-Cell Arteritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Giant-Cell Arteritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Giant-Cell Arteritis drugs and therapies

Giant-Cell Arteritis Pipeline Market Strengths

• Improved and clear treatment and diagnostic guidelines has led the patients and practitioners to clearly diagnose and treat the patients accurately.

• While glucocorticoids remain the primary treatment, there is ongoing research into alternative and adjunctive therapies, such as biologic agents like tocilizumab. This diversification in treatment options provides more tailored approaches for patients, considering factors like side effects and individual response.

Giant-Cell Arteritis Pipeline Market Opportunities

• The development of targeted biologic therapies offers a significant opportunity for improving treatment outcomes in GCA. Biologics, such as interleukin-6 (IL-6) inhibitors like tocilizumab, have shown promise in clinical trials. Further research and development in this area can lead to more effective and targeted treatments.

• The introduction of biosimilars for existing therapies can increase competition, potentially reducing treatment costs and improving accessibility for patients.

Scope of Giant-Cell Arteritis Pipeline Drug Insight

• Coverage: Global

• Key Giant-Cell Arteritis Companies: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others

• Key Giant-Cell Arteritis Therapies: Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others

• Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis current marketed and Giant-Cell Arteritis emerging therapies

• Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers

Request for Sample PDF Report for Giant-Cell Arteritis Pipeline Assessment and clinical trials

Table of Contents

1. Giant-Cell Arteritis Report Introduction

2. Giant-Cell Arteritis Executive Summary

3. Giant-Cell Arteritis Overview

4. Giant-Cell Arteritis- Analytical Perspective In-depth Commercial Assessment

5. Giant-Cell Arteritis Pipeline Therapeutics

6. Giant-Cell Arteritis Late Stage Products (Phase II/III)

7. Giant-Cell Arteritis Mid Stage Products (Phase II)

8. Giant-Cell Arteritis Early Stage Products (Phase I)

9. Giant-Cell Arteritis Preclinical Stage Products

10. Giant-Cell Arteritis Therapeutics Assessment

11. Giant-Cell Arteritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Giant-Cell Arteritis Key Companies

14. Giant-Cell Arteritis Key Products

15. Giant-Cell Arteritis Unmet Needs

16 . Giant-Cell Arteritis Market Drivers and Barriers

17. Giant-Cell Arteritis Future Perspectives and Conclusion

18. Giant-Cell Arteritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Giant-Cell Arteritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA, and Developments | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys

“Esophageal Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Esophageal Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years.

• Esophageal Cancer companies working in the treatment market are CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others, are developing therapies for the Esophageal Cancer treatment

• Emerging Esophageal Cancer therapies in the different phases of clinical trials are- CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.

• In March 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has announced today that the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA® (tislelizumab-jsgr) as a standalone treatment for adult patients suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone systemic chemotherapy that did not involve a PD-(L)1 inhibitor. TEVIMBRA is expected to be accessible in the U.S. market during the latter half of 2024.

• In February 2024, Elevation Oncology, Inc. (Nasdaq: ELEV), a forward-thinking oncology company dedicated to developing targeted cancer therapies for patients with various solid tumors and significant unmet needs, has announced the expansion of its ongoing Phase 1 clinical trial of EO-3021 beyond the United States. The first patient has been dosed in Japan. The trial aims to assess the safety, tolerability, and initial anti-tumor effects of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors that are likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, and esophageal cancers.

Esophageal Cancer Overview

Esophageal cancer is a type of cancer that forms in the esophagus, the long tube that carries food from the throat to the stomach. It typically develops in two main types: squamous cell carcinoma, which occurs in the cells lining the esophagus, and adenocarcinoma, which starts in the mucus-secreting glands of the esophagus. Risk factors include smoking, heavy alcohol use, acid reflux (gastroesophageal reflux disease or GERD), obesity, and certain dietary habits. Symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn. Treatment options often include surgery, chemotherapy, and radiation, depending on the stage of the disease. Early detection is crucial for improving survival rates.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:

• CDR404: CDR-Life Inc.

• M1231: Merck KGaA

• Sotigalimab: Apexigen

• Amivantamab: Genmab

• Telomelysin: Oncolys BioPharma Inc

• Tiragolumab: Genentech

• S-588410: Onco Therapy Science, Inc. /Shionogi & Co., Ltd.

• CS1001: CStone Pharmaceuticals

• Durvalumab: Celgene/MedImmune

• Tucatinib: Seagen

• APX 005M: Apexigen

• Erdafitinib: Janssen Research & Development, LLC

• Margetuximab: MacroGenics

• AN-0025: Adlai Nortye

Esophageal Cancer Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Esophageal Cancer Molecule Type

Esophageal Cancer Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment

• Esophageal Cancer Assessment by Product Type

• Esophageal Cancer By Stage and Product Type

• Esophageal Cancer Assessment by Route of Administration

• Esophageal Cancer By Stage and Route of Administration

• Esophageal Cancer Assessment by Molecule Type

• Esophageal Cancer by Stage and Molecule Type

DelveInsight’s Esophageal Cancer Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies

Some of the key companies in the Esophageal Cancer Therapeutics Market include:

Key companies developing therapies for Esophageal Cancer are – Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others.

Esophageal Cancer Pipeline Analysis:

The Esophageal Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.

• Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies

Esophageal Cancer Pipeline Market Drivers

• Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.

Esophageal Cancer Pipeline Market Barriers

• However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.

Scope of Esophageal Cancer Pipeline Drug Insight

• Coverage: Global

• Key Esophageal Cancer Companies: CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others

• Key Esophageal Cancer Therapies: CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others

• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies

• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Esophageal Cancer Report Introduction

2. Esophageal Cancer Executive Summary

3. Esophageal Cancer Overview

4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Esophageal Cancer Pipeline Therapeutics

6. Esophageal Cancer Late Stage Products (Phase II/III)

7. Esophageal Cancer Mid Stage Products (Phase II)

8. Esophageal Cancer Early Stage Products (Phase I)

9. Esophageal Cancer Preclinical Stage Products

10. Esophageal Cancer Therapeutics Assessment

11. Esophageal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Esophageal Cancer Key Companies

14. Esophageal Cancer Key Products

15. Esophageal Cancer Unmet Needs

16 . Esophageal Cancer Market Drivers and Barriers

17. Esophageal Cancer Future Perspectives and Conclusion

18. Esophageal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech, OncoTherapy